Partnerships Archives

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jan 2023

Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer

Ajinomoto Co., Inc. has signed a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of some of Exelixis’ antibody-drug conjugate (ADC) programs. Exelixis is an oncology-focused biotechnology company looking to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Utilizing its […]

January 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

AbbVie bets on Anima mRNA modulators to tackle cancer

AbbVie and Anima Biotech have announced a collaboration to discover and develop mRNA biology modulators for three targets in oncology and immunology. Anima Biotech will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets, providing AbbVie exclusive rights to license and further develop and commercialize the programs. “This collaboration […]

January 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

Selecta and Astellas sign LOPD treatment agreement

Selecta Biosciences, Inc. and Astellas Pharma Inc. have announced an exclusive licensing and development agreement for IdeXork (Xork). Xork is being studied as a potential next generation immunoglobulin G (IgG) protease that will be developed by Astellas for use with AT845, an investigational, adeno-associated virus (AAV)-based treatment for late-onset Pompe disease (LOPD) in adults. Pompe […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

BC Platforms to collaborate on Singapore population health study

BC Platforms (BCP) has been selected to analyze and manage data collected from the Health for Life in Singapore (HELIOS) study, which forms part of the SG100K data set for Singapore’s National Precision Medicine program. The HELIOS study is a population cohort study established and led by the Lee Kong Chian School of Medicine (LKCMedicine) […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

Boehringer Ingelheim and 3T Biosciences to develop next-generation cancer immunotherapies

Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

STALICLA signs agreement with Novartis on neurodevelopmental disorders

STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs). Mavoglurant has previously been tested in more than 1,800 patients and demonstrated a good safety and […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 5 Jan 2023

Cancer Research UK and Turbine to partner on program

Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, has announced that it is partnering with Turbine AI, a tech-enabled biotech leveraging its proprietary Simulated Cell platform to solve complex diseases. The partnership will utilize Turbine AI’s platform to identify target patient populations […]

January 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Jan 2023

Hummingbird Bioscience and Synaffix to develop ADC program

Synaffix B.V. and Hummingbird Bioscience have entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation antibody drug conjugate (ADC) program using Synaffix technology. Synaffix is a biotechnology company focused on commercializing its clinical-stage platform technology for the development of ADCs. Hummingbird Bioscience is a data-driven precision biotherapeutics company using […]

January 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 29 Dec 2022

Watch: Zoetis looks for partnerships at BioFIT

Animal health company, Zoetis, has a pipeline of medicines, vaccines, diagnostics and technologies for livestock and pets. Active in more than 100 countries, Zoetis generated revenue of $7.8 billion in 2021, and has approximately 12,100 employees. The company recently announced a collaboration with the partners of the Pastoral Greenhouse Gas Research Consortium, and the New […]

December 29, 2022 - 1 minutemin - By Jim Cornall

News and Trends 23 Dec 2022

Mersana Therapeutics and Merck to develop novel ADCs

Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug conjugates (ADCs) directed against up to two targets. Immunosynthen, Mersana Therapeutics’ proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both […]

December 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Dec 2022

Merck and Kelun-Biotech collaborating on seven ADC cancer candidates

Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. “Advances in ADC technologies are yielding a new generation of candidates designed to more […]

December 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Dec 2022

InSitu Biologics and Mayo Clinic to co-develop anti-cancer therapeutics

InSitu Biologics, Inc. has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics. The company has developed an industry-leading platform technology for loading large doses of a variety of medications into a localized delivery matrix. Once injected, medication elutes from […]

December 23, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Partnerships

Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer

AbbVie bets on Anima mRNA modulators to tackle cancer

Selecta and Astellas sign LOPD treatment agreement

BC Platforms to collaborate on Singapore population health study

Boehringer Ingelheim and 3T Biosciences to develop next-generation cancer immunotherapies

STALICLA signs agreement with Novartis on neurodevelopmental disorders

Cancer Research UK and Turbine to partner on program

Hummingbird Bioscience and Synaffix to develop ADC program

Watch: Zoetis looks for partnerships at BioFIT

Mersana Therapeutics and Merck to develop novel ADCs

Merck and Kelun-Biotech collaborating on seven ADC cancer candidates

InSitu Biologics and Mayo Clinic to co-develop anti-cancer therapeutics

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!